|
Asensio-Lopez M.d.C., Ruiz-Ballester M., Pascual-Oliver S., Bastida-Nicolas F.J., Sassi Y., Fuster J.J., Pascual-Figal D., Soler F., Lax A. AEOL-induced NRF2 activation and DWORF overexpression mitigate myocardial I/R injury. Molecular Medicine. December 2025. 31. 10.1186/s10020-025-01242-1
AÑO: 2025; IF: 6.0
|
|
Asensio-Lopez M.d.C., Severino P., Lax A. Editorial: Advanced therapeutic strategies and safety profiles in heart failure with reduced ejection fraction: contextualizing recent findings. Frontiers in Pharmacology. 2025. 16. 10.3389/fphar.2025.1607362
AÑO: 2025; IF: 4.4
|
|
Pascual-Figal D, Lax A, Asensio Lopez MC. Circulating ST2, from biomarker to pathogenic mediator. Rev Esp Cardiol (Engl Ed). 2023 Sep;76(9):672-674. doi: 10.1016/j.rec.2023.02.012. Epub 2023 Apr 19. No abstract available. English, Spanish. PubMed PMID: 37085116.
AÑO: 2023; IF: 5.9
|
|
Lax A., Soler F., Fernandez del Palacio M.J., Pascual-Oliver S., Ballester M.R., Fuster J.J., Pascual-Figal D., Asensio-Lopez M.d.C. Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis. Molecular Therapy Nucleic Acids. 13 June 2023. 32:704-720. 10.1016/j.omtn.2023.04.031
AÑO: 2023; IF: 6.5
|
|
Roncalli J., Tronchère H., Lax A., Kunduzova O. Editorial: Myocardial Remodeling: Mechanisms and Translational Implications. Frontiers in Pharmacology. 26 May 2022. 13. 10.3389/fphar.2022.930387
AÑO: 2022; IF: 5.6
|